Neil Warnock, MD, MS, CHCQM

Senior Director
Bayer

Poster(s):

• (372) A retrospective cohort study examining the real-world disease progression, HCRU, and costs among patients with T2D with newly diagnosed CKD stage III or IV with and without finerenone use
  Wednesday, October 29, 2025